|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2010-8-20
|
|
pubmed:abstractText |
Spinal and bulbar muscular atrophy is a hereditary motor neuron disease caused by the expansion of a polyglutamine tract in the androgen receptor. At present there are no treatments for spinal and bulbar muscular atrophy, although leuprorelin suppressed the accumulation of pathogenic androgen receptors in a phase 2 trial. We aimed to assess the efficacy and safety of leuprorelin for spinal and bulbar muscular atrophy.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1474-4465
|
|
pubmed:author |
pubmed-author:AokiMasashiM,
pubmed-author:BannoHaruhikoH,
pubmed-author:FujimotoYasushiY,
pubmed-author:HasegawaKazukoK,
pubmed-author:IshikawaKinyaK,
pubmed-author:ItoShoichiS,
pubmed-author:Japan SBMA Interventional Trial for TAP-144-SR (JASMITT) study group,
pubmed-author:KanaiKazuakiK,
pubmed-author:KandaFumioF,
pubmed-author:KatsunoMasahisaM,
pubmed-author:KawashimaMotoshiM,
pubmed-author:MiyajimaHiroakiH,
pubmed-author:MizusawaHidehiroH,
pubmed-author:MoritaMitsuyaM,
pubmed-author:NakanoImaharuI,
pubmed-author:NakashimaKenjiK,
pubmed-author:NishizawaMasatoyoM,
pubmed-author:SasakiHidenaoH,
pubmed-author:ShimohataTakayoshiT,
pubmed-author:SobueGenG,
pubmed-author:SuzukiKeisukeK,
pubmed-author:TakeuchiYuY,
pubmed-author:TanakaFumiakiF,
pubmed-author:TsujiShojiS,
pubmed-author:TsujinoAkiraA,
pubmed-author:UchinoMakotoM,
pubmed-author:WatanabeYasuhiroY,
pubmed-author:YabeIchiroI,
pubmed-author:YamamotoTomotakaT,
pubmed-author:YamashitaTaroT
|
|
pubmed:copyrightInfo |
Copyright 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
875-84
|
|
pubmed:meshHeading |
pubmed-meshheading:20691641-Adult,
pubmed-meshheading:20691641-Aged,
pubmed-meshheading:20691641-Antineoplastic Agents, Hormonal,
pubmed-meshheading:20691641-Dose-Response Relationship, Drug,
pubmed-meshheading:20691641-Double-Blind Method,
pubmed-meshheading:20691641-Female,
pubmed-meshheading:20691641-Humans,
pubmed-meshheading:20691641-Japan,
pubmed-meshheading:20691641-Leuprolide,
pubmed-meshheading:20691641-Male,
pubmed-meshheading:20691641-Middle Aged,
pubmed-meshheading:20691641-Muscular Atrophy,
pubmed-meshheading:20691641-Muscular Atrophy, Spinal,
pubmed-meshheading:20691641-Severity of Illness Index,
pubmed-meshheading:20691641-Statistics, Nonparametric,
pubmed-meshheading:20691641-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial.
|
|
pubmed:affiliation |
Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
